Previous close | 4.8550 |
Open | 4.8100 |
Bid | 0.0000 x 2200 |
Ask | 0.0000 x 3100 |
Day's range | 4.5800 - 4.9100 |
52-week range | 2.3000 - 5.7300 |
Volume | 1,943,870 |
Avg. volume | 3,314,668 |
Market cap | 788.96M |
Beta (5Y monthly) | 1.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5930 |
Earnings date | 05 Nov 2020 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.83 |
The company reported positive results from a clinical trial for one of its most promising pipeline candidates.
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Kadmon Holdings (NYSE:KDMN) on Monday, setting a price target of $25, which is approximately 470.78% above the present share price of $4.38.
NEW YORK, March 05, 2020 -- Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full.